$AZN

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

VXUS offers broad international diversification across 8,800 stocks with a 0.05% expense ratio. International equities trade at 17x earnings versus 25x for U.S. stocks.

Pathos AI acquires majority stake in DeuterOncology to advance DO-2, a MET inhibitor showing 100% tumor shrinkage in Phase 1 with superior safety profile.

AstraZeneca's prostate drug Truqap wins FDA panel backing (7-1 vote) for PTEN-deficient tumors, but breast cancer candidate camizestrant rejected despite superior efficacy data.

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

AstraZeneca ($AZN) reported Q1 revenue of $15.29B, up 13% YoY, with oncology surging 20%. Shares fell 2.30% despite beating estimates.

FDA launches real-time clinical trial initiative with $AMGN and $AZN pilots, aiming to accelerate drug approvals and eliminate traditional reporting delays.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

Global antibiotic resistance market to grow from $9.78B (2026) to $12.72B (2031) at 5.4% CAGR, driven by rising drug-resistant infections and antimicrobial innovation.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

Clinical trial software market projected to grow from $1.32B in 2025 to $2.53B by 2030, driven by AI adoption and virtual trials.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Global vulvar cancer market expected to expand through 2035, driven by aging populations and HPV prevalence. Merck, Bristol Myers Squibb, and AstraZeneca lead innovation in immunotherapies despite reimbursement headwinds.

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Bispecific antibody drug conjugates market projected at $2B+ by 2030, with first approval expected by 2028 amid 150+ global clinical trials.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Targeted alpha therapy market surging with 30+ drugs in clinical trials. Major pharma M&A signals confidence in precision oncology's future.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.